Medbanks Health Technology Secures Nearly RMB 2 Billion in Series E1 Funding to Strengthen Integrated Healthcare Management System

VCBeat (WeChat ID: vcbeat) has learned that on December 21, Medbanks Health Technology announced the completion of its Series E1 financing round, raising nearly RMB 2 billion. The round was co-led by Tencent and Jeneration Capital, with participation from Five Source Capital, Forebright Capital, Shuanghu Capital, and a large insurance private equity fund. Taihe Capital served as the exclusive financial advisor. As a rapidly growing unicorn in the healthcare sector, Medbanks’ latest funding represents the largest single investment in the pharmaceutical and healthcare industry this year. Following the completion of this round, the company will further strengthen its closed-loop ecosystem in pharmaceuticals and healthcare, continuing to expand its leading position in the industry.

Founded in 2014, Medbanks Health Technology has built China’s leading clinical trial management organization and the nation’s premier specialty drug management network by addressing the core needs of patients and physicians. It has further integrated patients, healthcare institutions, pharmaceutical companies, and insurance payers to establish a true closed-loop service ecosystem for pharmaceuticals and health insurance, thereby forming three core business segments and creating a “UnitedHealth” model with Chinese characteristics.

Currently, Medbanks has established China’s largest clinical institution management organization for oncology, covering 100% of core physicians and 100% of core hospitals in the field. It has formed close clinical collaborations with hundreds of domestic, innovative, and multinational pharmaceutical companies, becoming the leading brand in China’s oncology SMO sector.

Leveraging the healthcare network established by its SMO business, Medbanks continues to expand into DTP (Direct-to-Patient) specialty pharmacies. Within three years, it has deployed nearly 80 specialty pharmacies across China with unified service standards and systematic layout, covering 56 cities in 29 provinces and serving hundreds of thousands of patients. With “professionalism” as its core positioning, Medbanks Pharmacy has established an independent medical department to lead professional pharmaceutical care services, developed a dedicated patient management system, and set industry standards for pharmaceutical care management.

By integrating the infrastructure networks of physicians, medical institutions, and pharmaceutical companies, Medbanks has further streamlined commercial insurance payments to establish a multi-tiered healthcare security network. Currently, Medbanks has implemented inclusive supplementary medical insurance in multiple regions and launched its next-generation corporate health and wellness benefits solution—Medbanks Health Insurance. Adopting a model of proactive management by corporate physicians, Medbanks Health Insurance completes the commercial insurance closed loop of claims occurrence, service delivery, and reimbursement within Medbanks’ self-built healthcare ecosystem. It is rapidly expanding across China, helping enterprises accelerate their growth through high-quality and efficient medical services, thereby advancing toward the corporate vision of “providing reliable healthcare protection for strivers and their families.”

CFO Zhou Tengstated: “We extend our gratitude to both new and existing investors for their trust in Medbanks and their recognition of our long-term objectives. China’s healthcare industry is currently experiencing a historic opportunity for comprehensive reform and upgrading. The demand from every household for trustworthy, compassionate medical management and higher-quality healthcare coverage has opened up a broad and long runway for growth. Medbanks aims to strive within this industry to effectively address unmet needs in medical care and health management, undertaking initiatives that benefit both physicians and patients. Upholding a profound respect for the medical profession, we are committed to providing reliable healthcare protection and creating social value.”

Lead Investor of This RoundZhang Ziquan, Partner at Jeneration CapitalJeneration Capital stated, “The market for specialty drugs and innovative health insurance is inherently vast and rapidly expanding, while recent healthcare reforms have brought new industry opportunities to this sector. Against the backdrop of these dual policy and commercial opportunities, Jeneration Capital is highly optimistic about Medbanks’ positioning and business model. We strongly align with Medbanks’ vision of value-based healthcare, which creates value for participants across the value chain and fosters a virtuous cycle between service providers and payers. Furthermore, Jeneration Capital highly recognizes the management team led by founder Ma Xuguang. Leveraging their extensive experience in the pharmaceutical and healthcare industries, profound insights, and first-class execution capabilities, they have created significant and long-term value for the ecosystem of specialty drugs and innovative health insurance.”

Jiang Ke, Partner at Taihe Capital“It stated: ‘As healthcare reform deepens, China’s multi-tiered medical security system is evolving toward managed care. The National Healthcare Security Administration effectively functions as the largest HMO, leveraging its strong bargaining power to reduce costs and expand coverage. Market-oriented, HMO-like institutions assume differentiated roles in supplemental payment, service upgrades, and supply chain transformation. Consequently, an increasing number of “China-style UnitedHealth” narratives are emerging. However, few companies have solidly built a tripartite infrastructure integrating pharmaceuticals, healthcare services, and insurance, while maintaining robust operational control, as Medbanks has done. This achievement stems from the team’s profound understanding and keen insight into the changes at both ends and along the dual tracks of the healthcare market, coupled with strong strategic capabilities and execution, as well as an unwavering commitment to “providing reliable healthcare protection for strivers and their families.” Taihe is honored to accompany the company on this journey, contributing to both commercial and social value.’”